

SPECIFICATION AMENDMENTS

Please amend page 6, line 31 to page 7, line 1 to read as follows:

According to the present invention this object is solved by a method ~~according to claim 1 and a medicament according to claims 16 to 18~~ using specific DNazymes according to ~~claims 10 to 15~~ the present invention as defined herein after.

Please insert the following on page 7, following line 1:

The invention relates to a DNzyme which binds to GATA-3 mRNA and functionally inactivates it, which comprises:

- a catalytic domain with the nucleotide sequence GGCTAGCTACAACGA SEQ ID NO: 154 or a modified sequence with comparable biological effect, which cleaves the GATA-3 mRNA at every purine:pyrimidine binding site to which it is bonded,
- a right substrate binding domain adjoining the 3' end of the catalytic domain having polynucleotide sequence GTCTTGAG and
- a left substrate binding domain adjoining the 5' end of the catalytic domain having polynucleotide sequence GTGGATGGA, both substrate binding domains being respectively complementary to two regions of the GATA 3 mRNA so that they hybridize with the mRNA, and

- which is active in vivo.

In a preferred feature of the invention, the DNzyme comprises sequence hgd 40 GTGGATGGA GGCTAGCTACAACGA GTCTTGGAG which is SEQ ID NO: 40.

In particular the invention relates to a DNzyme which cleaves the catalytic domain of the GATA-3 mRNA at every purine:uracil binding site.

Furthermore the DNzyme according to the present invention is stabilized against decomposition within the organism by introduction of a 3'-3' inversion.

Another preferred feature of the invention relates to a DNzyme which is stabilized against decomposition within the organism by introduction of modified nucleotides or nucleotide compounds.

A particular feature of the invention relates to a DNzyme which includes an inverse thymidine on the 3' end and/or a FAM label on the 5' end.

The invention also relates to A medicament containing a DNzyme according to the present invention and a pharmaceutically acceptable carrier.

Please amend page 7, following line 17 to insert the following:

Brief Description of the Drawings.